Mofilox
Mofilox (MOXIFLOXACIN) Macter USP tablets are 400 mg, a broad-spectrum antibiotic, 5 film coated tablets. It is a fluoroquinolone antibiotic used to treat a variety of bacterial infections.
Moxifloxacin exhibits in vitro activity against a wide range of Gram-positive and Gram-negative microorganisms. The bacterial action of moxifloxacin results in the inhibition of topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair, and recombination.
Package contains: Each package of Mofilox contains 5 tablets of 400 mg & a leaflet.
Composition: Each film coated tablet contains:
Moxifloxacin as hydrochloride USP 400 mg.
USP Specifications.
Dosage: As directed by a registered medical practitioner.
Indication & Usage: Moxifloxacin is indicated for the treatment of adults 18 years of age with infections caused by susceptible strains of the designated microorganisms in the conditions listed below.
- Acute Bacterial Sinusitis.
- Acute Bacterial Exacerbation of Chronic Bronchitis.
- Community required pneumonia.
- Complicated Uncomplicated Skin and Skin Structure infections.
- Complicated intra-Abdominal Infections.
- Moxifloxacin has been shown to be active against most strains of the following microorganisms both at vitro and in clinical infections.
Dosage & administration: The oral dose of moxifloxacin is 400mg once in a day. The duration of therapy depends on the type of infection, given below.
- Acute Bacterial Sinusitis, 400 mg, use for 10 days.
- Acute Bacterial Exacerbation of Chronic Bronchitis, 400 mg, use for 6 days.
- Community required Pneumonia, 400 mg, use for 7-14 days.
- Uncomplicated Sun and Skin Structure infections, 400 mg, use for 7 days.
- Complicated Skin and Skin Structure infections, 400 mg, use for 7-21 days.
- Complicated Intra-Abdominal infections, 400 mg, use for 5-14 days.
Contradiction: Moxifloxacin is contraindicated in patients with a history of hypersensitivity to moxifloxacin or any member of the quinolone class of antimicrobial agents.
Warnings & Special Precautions: The safety and effectiveness of moxifloxacin in paediatric patients, adolescents (Less than 18 years of age, pregnant women, and lactating women have not been established.
Pregnancy: Teratogenic Effects. Pregnancy Category C. Since there are no adequate or well-controlled studies in pregnant women, moxifloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Quinolones may cause central nervous system (CNS) events, including nervousness, agitation, insomnia, anxiety, nightmares, or paranoia.
Nursing Mothers: Moxifloxacin is excreted in the breast milk. Because of the potential for serious adverse reactions in infants who are nursing from mothers taking moxifloxacin, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Adverse Effects: Most adverse events reported in moxifloxacin were described as mild to moderate in severity and required no treatment. Additional clinically relevant uncommon events that occurred in greater than or equal to 0.15% and less than 2% of moxifloxacin-treated patients were:
Body as a whole: abdominal pain, headache, asthenia. Injection site reaction (including phlebitis), malaise, moniliasis pain, allergic reaction.
Cardiovascular tachycardia, palpitation, vasodilation, QT interval prolonged.
Digestive: vomiting, abnormal liver function test, dyspepsia, dry mouth, flatulence, oral moniliasis, constipation, GGTP increased, anorexia, stomatitis, glossitis.
Hemic and Lymphatic: leukopenia, eosinophilia, prothrombin decrease. Metabolic and Nutritional: lactic dehydrogenase increased, and amylase increased.
Musculoskeletal: arthralgia, myalgia.
Nervous System: insomnia, nervousness, vertigo, somnolence, anxiety, tremor.
Skin/ Appendages: rash (maculopapular, purpuric, pustular), pruritus, sweating, urticarial.
Special Senses: taste perversion.
Urogenital: vaginal moniliasis, vaginitis.
Interactions: No clinically significant drug interactions between itraconazole, theophylline, warfarin, digoxin, atenolol, oral contraceptives, or glyburide have b
een observed with moxifloxacin. Itraconazole, theophylline, digoxin, probenecid, morphine, ranitidine, and calcium have been shown not to significantly alter the pharmacokinetics of moxifloxacin.
Instructions: Store at 25°C. (Excursions permitted to 15°C to 30°C). Protect from light, heat, and moisture. Keep all medicines out of the reach of children. To be sold on the prescription of a registered medical practitioner only. For detailed information, see the direction circular inside.
Manufactured & Buy Online:
Mofilox tablets are manufactured by: Macter International Limited.
This is the link to the manufacturer: https://macter
Buy online: https://chemistdirect.pk
You can also buy it from any nearby pharmacy.